FDA PMA
FDA Class 3
Approved
🇺🇸 United States
Coronary Drug-Eluting Stent
PMA: P110019
·
Supplement: S124
·
Decision Oct 4, 2023
Classifications
1
FEI Numbers
32
Registration Numbers
32
Basic Information
- Device Name
- Coronary Drug-Eluting Stent
- Trade Name
- XIENCE Skypoint Everolimus Eluting Coronary Stent System
- PMA Number
- P110019
- Supplement Number
- S124
- Device Class
- FDA Class 3
- Product Code
- NIQ
- Generic Name
- Coronary drug-eluting stent
- Medical Specialty
- Unknown
- Advisory Committee
- Cardiovascular
- Decision
- Approved
- Decision Code
- APPR
- Decision Date
- October 4, 2023
- Date Received
- March 30, 2023
- Supplement Type
- Normal 180 Day Track
- Supplement Reason
- Change Design/Components/Specifications/Material
- Expedited Review
- N
Advisory Committee Statement
Approval for an expansion of the size matrix to include a 48 mm length for the stent diameters 2.50, 2.75, 3.00, 3.50 and 4.00 mm
Classifications
This FDA Pre-Market Approval entry is associated with 1 FDA classification via its product code.
| Product Code | Device Name | Device Class | Medical Specialty |
|---|---|---|---|
| NIQ | Coronary Drug-Eluting Stent | FDA class 3 | Unknown |